

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities in the Company.



BIOSYSEN LIMITED

生物系統工程有限公司

*(formerly known as “Legend Strategy International Holdings Group Company Limited
枋濬國際集團控股有限公司”)*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1355)

COMPLETION OF THE ISSUE OF CONVERTIBLE BONDS UNDER SPECIFIC MANDATE

References are made to (i) the circular of Biosysen Limited (the “**Company**”) dated 8 July 2026 (the “**Circular**”) in relation to, among others, the Subscription; and (ii) the announcement of the Company dated 27 July 2026 in relation to the poll results of the EGM. Capitalised terms used herein shall have the same meanings as those defined in the Circular unless defined otherwise.

COMPLETION OF THE ISSUE OF CONVERTIBLE BONDS

The Board is pleased to announce that all the conditions precedent as set out in the Subscription and Settlement Agreement have been fulfilled and the Completion took place on 5 August 2026. Upon Completion, the Convertible Bonds in the aggregate principal amount of HK\$50.0 million were issued to the Subscriber. The subscription price of the Convertible Bonds was settled by the Subscriber by way of set-off against the Set-off Loan, and the Company’s repayment obligations in respect of the Set-off Loan were thereby fully discharged. None of the Convertible Bonds is converted as at the date of this announcement.

EFFECT OF THE SHAREHOLDING STRUCTURE OF THE COMPANY

For illustration purposes only, the table below demonstrates the shareholding structure of the Company (i) as at the date of this announcement; and (ii) immediately upon full exercise of the conversion rights attaching to the Convertible Bonds at the initial Conversion Price:

Shareholders	As at the date of this announcement		Upon full exercise of the conversion rights attaching to the Convertible Bonds at the initial Conversion Price (Note 1)	
	Number of Shares	Approx. %	Number of Shares	Approx. %
The Subscriber (Note 2)	345,929,020	28.99%	668,509,665	44.11%
Li Baoshan	93,940,000	7.87%	93,940,000	6.20%
Kwan Man Cheuk	66,082,000	5.54%	66,082,000	4.36%
Public Shareholders	687,114,140	57.60%	687,114,140	45.33%
Total	<u>1,193,065,160</u>	<u>100%</u>	<u>1,515,645,805</u>	<u>100%</u>

Notes:

1. These figures are based on the assumption that there will be no change in the number of issued Shares from the date of this announcement to the date of exercise, and they have not taken into account the Company's proposed rights issue as disclosed in its announcement dated 24 June 2026.
2. The Subscriber is indirectly wholly-owned by Mr. Cheung Ching Mo, a non-executive Director.
3. The table above is for illustrative purposes only, and conversion of the Convertible Bonds is subject to the restriction that no conversion shall trigger mandatory offer obligation under the Takeovers Code.
4. Certain percentage figures included in the above table have been subject to rounding adjustments. Accordingly, figures shown as totals may not be an arithmetic aggregation of the figures preceding them.

By order of the Board
Biosysen Limited
Lee Tsz Yan
Executive Director

Hong Kong, 5 August 2026

As at the date of this announcement, the Board comprises Ms. Lee Tsz Yan as executive Director; Mr. Cheung Ching Mo and Mr. Hu Xinglong as non-executive Directors; and Mr. Wu Jilin, Mr. Lam Cheung Shing Richard and Mr. So Yin Wai as independent non-executive Directors.